Plus Therapeutics, Inc. announced on July 8, 2025, the successful treatment of its initial patients in the ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re 186 obisbemeda). This trial is designed for the treatment of leptomeningeal metastases (LM).
The dose optimization trial builds on promising results from the company’s completed Phase 1 single-dose escalation study, which demonstrated the feasibility of REYOBIQ for treating LM. The trial is designed in alignment with the FDA’s Project Optimus to identify the optimal dosing regimen that maximizes efficacy and safety.
The study aims to determine the safety and tolerability of multiple REYOBIQ doses administered via intraventricular catheter at defined intervals. It also seeks to identify both the maximum tolerated dose and minimum effective dose, with enrollment expected to proceed rapidly.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.